Lifeward Ltd. (LFWD)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lifeward Ltd. (LFWD) trades at $9.14 with AI Score 45/100 (Grade C). Lifeward Ltd. is a medical device company focused on developing and commercializing mobility and wellness technologies for individuals with physical and neurological conditions. Market cap: $14.72M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for LFWD: LFWD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LFWD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LFWD: the 1 perspectives are evenly split.
How is this calculated? →Lifeward Ltd. (LFWD) Healthcare & Pipeline Overview
Lifeward Ltd. designs and commercializes medical devices, including exoskeletons and soft exo-suits, aimed at improving mobility and wellness for individuals with physical and neurological conditions. Operating globally, the company serves both institutions and individuals, positioning itself in the rehabilitation and assistive technology market.
What Is the Investment Thesis for LFWD?
Lifeward Ltd. operates in the growing medical device market, specifically targeting the rehabilitation and assistive technology sectors. With a market capitalization of $14.72M, the company's potential lies in the increasing demand for mobility solutions for individuals with physical and neurological conditions. Key value drivers include the expansion of their product line, particularly the ReStore and ReBoot soft exo-suits, and strategic partnerships to broaden market reach. While the company currently has a negative P/E ratio of -0.31 and a negative profit margin of -121.8%, successful commercialization and cost management could improve profitability. Ongoing catalysts include continued innovation in exoskeleton technology and favorable regulatory approvals for new products.
Based on FMP financials and quantitative analysis
LFWD Key Highlights
- Market capitalization of $14.72M indicates the company's current valuation in the market.
- Gross margin of 37.5% reflects the profitability of Lifeward's products before operating expenses.
- Negative P/E ratio of -0.31 suggests the company is currently not profitable.
- Profit margin of -121.8% indicates significant operating losses.
- Beta of 0.14 suggests the stock is less volatile than the overall market.
Who Are LFWD's Competitors?
LFWD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| IINN Inspira Technologies Oxy B.H.N. Ltd. | $1.61 | -1.83% | $38.77M | 46 |
| INAB IN8bio, Inc. | $1.43 | +0.70% | $13.71M | 31 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LFWD's Key Strengths?
- Innovative exoskeleton and soft exo-suit technology.
- Established presence in the rehabilitation market.
- Diverse product portfolio targeting various mobility impairments.
- Global distribution network.
What Are LFWD's Weaknesses?
- Negative profitability and high operating losses.
- Limited market capitalization.
- Dependence on regulatory approvals.
- Competition from larger medical device companies.
What Could Drive LFWD Stock Higher?
- Regulatory approvals for new products and indications.
- Expansion of sales and marketing efforts.
- Strategic partnerships with rehabilitation centers and hospitals.
- Technological advancements in exoskeleton technology.
What Are the Key Risks for LFWD?
- Financial-distress signal — its Altman Z-Score of -13.12 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory setbacks and delays.
- Product liability claims.
- Competition from established medical device companies.
- Economic downturns affecting healthcare spending.
- Negative profitability and high operating losses.
What Are the Growth Opportunities for LFWD?
- Expansion of ReStore soft exo-suit: The market for stroke rehabilitation devices is substantial, with a growing need for effective therapies to improve motor function. Lifeward's ReStore soft exo-suit has the potential to capture a significant share of this market. The global stroke rehabilitation market is projected to reach billions of dollars in the coming years, offering substantial revenue potential for Lifeward. Timeline: Ongoing.
- Commercialization of ReBoot personal exo-suit: The ReBoot personal soft exo-suit targets individuals post-stroke for home and community use, expanding Lifeward's reach beyond clinical settings. This device addresses the need for accessible and convenient rehabilitation solutions, tapping into a growing market for personal healthcare devices. The market for personal rehabilitation devices is expected to grow as technology advances and healthcare shifts towards more personalized care. Timeline: Ongoing.
- Strategic partnerships and distribution agreements: Collaborating with rehabilitation centers, hospitals, and distributors can significantly expand Lifeward's market reach and accelerate product adoption. Strategic alliances can provide access to new markets and customer segments, enhancing the company's competitive position. These partnerships can also facilitate the integration of Lifeward's products into existing rehabilitation programs and protocols. Timeline: Ongoing.
- Technological advancements in exoskeleton technology: Continuous innovation in exoskeleton technology, including improved battery life, lighter materials, and enhanced functionality, can drive product differentiation and market adoption. Investing in research and development to enhance the performance and usability of exoskeletons can attract a wider range of users and applications. Timeline: Ongoing.
- Expansion into new geographic markets: Expanding into new geographic markets, particularly in developing countries with growing healthcare infrastructure, can unlock significant growth opportunities for Lifeward. These markets often have unmet needs for rehabilitation and assistive technologies, providing a favorable environment for Lifeward's products. Timeline: Ongoing.
What Opportunities Does LFWD Have?
- Expansion into new geographic markets.
- Strategic partnerships with rehabilitation centers and hospitals.
- Technological advancements in exoskeleton technology.
- Increasing demand for rehabilitation and assistive devices.
What Threats Does LFWD Face?
- Intense competition in the medical device industry.
- Regulatory hurdles and reimbursement challenges.
- Product liability risks.
- Economic downturns affecting healthcare spending.
What Are LFWD's Competitive Advantages?
- Proprietary exoskeleton technology.
- Established brand recognition in the rehabilitation market.
- Distribution network with access to key customer segments.
- Intellectual property protection through patents.
What Does LFWD Do?
Lifeward Ltd., formerly known as ReWalk Robotics Ltd., was founded in 2001 and is headquartered in Yokneam Illit, Israel. The company focuses on developing and marketing technologies that aid mobility and wellness for individuals with physical and neurological conditions. Lifeward's product line includes ReWalk, a personal exoskeleton system designed to enable individuals with spinal cord injuries to stand and walk again, and ReStore, a soft exo-suit intended for stroke rehabilitation. They also offer the AlterG Anti-Gravity System, utilized in physical and neurological rehabilitation, as well as athletic training, and MyoCycle devices. The ReBoot, a personal soft exo-suit for post-stroke individuals, is also part of their offerings. Lifeward sells its products directly to institutions and individuals, and through third-party distributors, reaching markets in the United States, Europe, the Asia-Pacific region, and other international locations. The company rebranded to Lifeward Ltd. in September 2024, signaling a broader focus on overall wellness and mobility solutions.
What Products and Services Does LFWD Offer?
- Designs and develops exoskeleton systems for individuals with spinal cord injuries.
- Offers soft exo-suits for stroke rehabilitation.
- Provides anti-gravity systems for physical and neurological rehabilitation.
- Manufactures MyoCycle devices for therapeutic exercise.
- Commercializes ReBoot, a personal soft exo-suit for post-stroke individuals.
- Markets and sells products directly to institutions and individuals.
- Distributes products through third-party partners.
How Does LFWD Make Money?
- Direct sales to hospitals, rehabilitation centers, and clinics.
- Sales to individuals for personal use.
- Distribution agreements with third-party partners.
- Revenue from product maintenance and service contracts.
What Industry Does LFWD Operate In?
Lifeward Ltd. operates within the medical device industry, which is characterized by continuous innovation and increasing demand for advanced healthcare solutions. The market for rehabilitation and assistive technologies is growing, driven by an aging population, rising prevalence of neurological disorders, and increasing awareness of the benefits of mobility assistance. The company competes with other medical device manufacturers and technology companies in this space. The industry is subject to regulatory oversight, technological advancements, and evolving reimbursement policies.
Who Are LFWD's Key Customers?
- Hospitals and rehabilitation centers.
- Individuals with spinal cord injuries.
- Individuals recovering from stroke.
- Athletic training facilities.
Key Financial Metrics
Return on assets is -77.4%, showing how much profit it generates from its asset base. A current ratio of 2.40 indicates the company holds enough short-term assets to cover its near-term obligations.
Lifeward Ltd. (LFWD) Valuation Context
Valued at $14.72M, LFWD is classified as a micro-cap stock. Relative to its peer group, LFWD's quantitative score of 45/100 is below the peer average of 59/100.
Company Profile
Lifeward Ltd. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Yokneam Illit, IL. The company is led by CEO William Mark Grant. LFWD has traded publicly since 2014.
F-Score 3/9Financial Health
Lifeward Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.12 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Lifeward Ltd. revenue of about $28.3M for fiscal 2026, with EPS near $-4.43.
Net buyingInsider Activity
Over the past six months, Lifeward Ltd. insiders filed 8 SEC Form 4 transactions — 0 sales and 8 purchases. On net that is roughly 274K shares acquired (about $1.4M) — insiders putting money in tends to read as conviction.
LFWD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Lifeward's recent strategic partnerships suggest a move towards expanding their market reach, potentially leading to increased adoption of their platform.
- Insiders buying shares lately could signal strong belief in the company's future prospects, boosting investor confidence.
- Positive community sentiment indicates growing excitement around Lifeward's innovative approach to personalized learning.
- The general market perception seems to view Lifeward as a disruptor in the education technology space, attracting attention from venture capitalists and strategic investors.
Bear Case
- Mixed community feedback raises concerns about the user experience and platform scalability, potentially hindering widespread adoption.
- Recent insider selling, even if for personal reasons, might create uncertainty among retail investors about the company's short-term prospects.
- Increased competition in the personalized learning market could put pressure on Lifeward's market share and profitability.
- The company's reliance on a specific technology could make it vulnerable to obsolescence if a superior alternative emerges, similar to how Blackberry struggled against Apple.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
LFWD Latest News
-
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
globenewswire.com · May 19, 2026
-
How The Lifeward (LFWD) Story Is Shifting With New Price Targets And Valuation Assumptions
Yahoo! Finance: LFWD News · May 17, 2026
-
Lifeward Ltd (LFWD) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing Growth ...
Yahoo! Finance: LFWD News · May 15, 2026
-
Lifeward (LFWD) Q1 2026 Earnings Transcript
Yahoo! Finance: LFWD News · May 15, 2026
LFWD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LFWD.
Price Targets
Wall Street price target analysis for LFWD.
LFWD MoonshotScore
What does this score mean?
The MoonshotScore rates LFWD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
How The Lifeward (LFWD) Story Is Shifting With New Price Targets And Valuation Assumptions
Lifeward Ltd (LFWD) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing Growth ...
Lifeward (LFWD) Q1 2026 Earnings Transcript
Lifeward Ltd. Healthcare Stock: Key Questions Answered
What does Lifeward Ltd. do?
Lifeward Ltd. is a medical device company that designs, develops, and commercializes technologies aimed at improving mobility and wellness for individuals with physical and neurological conditions. Their primary products include exoskeletons (ReWalk), soft exo-suits (ReStore and ReBoot), and anti-gravity systems (AlterG). These devices are used in rehabilitation settings and for personal use, helping individuals with spinal cord injuries, stroke, and other mobility impairments to regain function and improve their quality of life. The company operates globally, serving both institutions and individuals through direct sales and third-party distributors.
What are the main risks for LFWD?
Lifeward Ltd. faces several risks inherent to the medical device industry. These include regulatory hurdles and the need for approvals from bodies like the FDA and EMA, which can be time-consuming and costly. Product liability is another significant risk, given the nature of their devices and the potential for injury. Competition from larger, more established medical device companies also poses a threat. Additionally, economic downturns can affect healthcare spending, impacting the demand for Lifeward's products. The company's current negative profitability and high operating losses also present a financial risk.
What are the key factors to evaluate for LFWD?
Lifeward Ltd. (LFWD) holds an AI score of 45/100 (low). Not financial advice.
How frequently does LFWD data refresh on this page?
LFWD prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LFWD's recent stock price performance?
Lifeward Ltd. (LFWD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative exoskeleton and soft exo-suit technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LFWD overvalued or undervalued right now?
Valuing Lifeward Ltd. (LFWD) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LFWD?
Before investing in Lifeward Ltd. (LFWD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding LFWD to a portfolio?
Key strength of Lifeward Ltd. (LFWD): Innovative exoskeleton and soft exo-suit technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on publicly available information.
- AI analysis is pending and may provide additional insights.
- This dossier is for informational purposes only and does not constitute investment advice.